HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Inovio Pharmaceuticals (INO) Investors with Significant Losses to Contact its Attorneys: Securities Fraud Class Action Filed
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: GlobeNewswire
SAN FRANCISCO, March 16, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims. Class Period: Feb. 14, 2020 - Mar. 9, 2020Lead Plaintiff Deadline: May 12, 2020Sign Up: www.hbsslaw.com/investor-fraud/INOContact An Attorney Now: INO@hbsslaw.com844-916-0895 Inovio (INO) Securities Class Action: The complaint alleges that Defendants made misleading statements about Inovio’s development of a purported vaccine for the novel coronavirus. Specifically, in a Feb. 14, 2020 televised interview, Inovio CEO J. Joseph Kim stated that Inovio had developed a COVID-19 vaccine “in a matter of about three hours once we had the DNA sequence from the virus.” Then, in a well-publicized Mar. 2, 2020 COVID-19 meeting with President Trump, Kim again claimed “we were able to fully
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- Human Papillomavirus Market is Projected to Boost at a Moderate Growth Rate During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at HC Wainwright from $12.00 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $33.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Royal Bank of Canada from $7.00 to $6.00. They now have a "sector perform" rating on the stock.MarketBeat
INO
Earnings
- 11/14/24 - Beat
INO
Sec Filings
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 11/8/24 - Form SC
- INO's page on the SEC website